[1]杨再林,张勇,张伶,等.硼替佐米联合化疗对多发性骨髓瘤的疗效与相关血液学指标分析[J].第三军医大学学报,2010,32(09):975-978.
 Yang Zailin,Zhang Yong,Zhang Ling,et al.Effect of bortezomib in combination with chemotherapy on multiple myeloma and change in its hematological indexes[J].J Third Mil Med Univ,2010,32(09):975-978.
点击复制

硼替佐米联合化疗对多发性骨髓瘤的疗效与相关血液学指标分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
32卷
期数:
2010年第09期
页码:
975-978
栏目:
论著
出版日期:
2010-05-15

文章信息/Info

Title:
Effect of bortezomib in combination with chemotherapy on multiple myeloma and change in its hematological indexes
作者:
杨再林张勇张伶夏顺中裴莉符刚秦大兵白海雁田小波朱艳陈润徐双年陈洁平
第三军医大学西南医院血液病中心;重庆医科大学医学检验系临床检验诊断学教育部重点实验室
Author(s):
Yang ZailinZhang YongZhang LingXia ShunzhongPei LiFu GangQin DabingBai HaiyanTian XiaoboZhu YanChen RunXu ShuangnianChen Jieping
Center of Hematology,Southwest Hospital,Third Military Medical University,Chongqing, 400038; Faculty of Laboratory Medicine, Key Laboratory of Laboratory Medical Diagnostics,  Ministry of Education, Chongqing Medical University,  Chongqing, 400016, China
关键词:
多发性骨髓瘤硼替佐米疗效不良反应血液学指标
Keywords:
multiple myelomabortezomibefficacytoxicitieshematological index
分类号:
R730.53;R733.3;R979.12
文献标志码:
A
摘要:
目的   观察硼替佐米治疗多发性骨髓瘤(multiple myeloma ,MM)的疗效及血液学指标的改变。   方法   2007年4月至2009年12月本院血液病中心收治的18例多发性骨髓瘤患者,其中7例初治患者与11例复发难治患者,均采用以硼替佐米为主的联合方案化疗,3周为1个疗程,每例患者至少接受1~6个疗程的治疗。观察疗效及相关血液学指标的改变。   结果   7例初治患者中5例患者完全缓解(CR),后1例行自体造血干细胞移植,2例患者获得部分缓解(PR)。11例复发难治患者中7例达CR,2例达PR,2例无效。患者浆细胞比例、血清总蛋白含量(TP)、球蛋白(G)、M蛋白含量、尿蛋白、β2-微球蛋白、乳酸脱氢酶(LDH)、肌酐(Cr)、尿酸(UA)等随化疗周期呈明显下降趋势,患者血红蛋白(Hb)、白蛋白(Alb)含量、A/G比值等呈明显的上升趋势。不良反应多为1~2级,常为一过性,包括周围神经病变(4/18)、骨痛(1/18)、胃肠道反应(8/18),经对症治疗后均好转。   结论   硼替佐米对初发及难治复发多发性骨髓瘤的治疗均有较好疗效,对治疗相关不良反应患者可耐受,相关血液学指标改善明显。
Abstract:
Objective   To observe the therapeutic effect of bortezomib on multiple myeloma (MM) and the change in its hematological indexes.     Methods   Of the 18 patients with MM admitted to Hematopathy Center, Third Military Medical University from April 2007 to December 2009, 7 had newly diagnosed MM and 11 had relapsed or refractory MM. MM was treated with bortezomib in combination with chemotherapy, 3 weeks a course, for at least 1 to 6 courses, to observe its effect and change in hematological indexes.     Results   Complete remission (CR) of MM was achieved in 5 out of the 7 patients with newly diagnosed MM. Of the 5 patients, 1 received autologous hematopoietic stem cell transplantation and 2 had a partial response (PR). Of the 11 patients with refractory or relapsed MM, 2 had a PR, 7 had CR, and 2 had no response (NR). The number of plasma cells and the levels of serum total protein (TP), globulin (G), M protein, urine protein, β2-microglobulin, lactate dehydrogenase (LDH), creatinine (Cr), and urine acid (UA) decreased significantly with the cycle of chemotherapy. However, the hemoglobin (Hb) and albumin (Alb) level and A/G ratio increased significantly. The main side effects included peripheral neuropathy, ostealgia and gastrointestinal disorders, which were transient and improved after treatment.    Conclusion   Bortezomib is effective against newly-diagnosed refractory and relapsed MM, with acceptable side effects, and can significantly improve the related hematological indexes.

参考文献/References:

杨再林, 张勇, 张伶, 等.硼替佐米联合化疗对多发性骨髓瘤的疗效与相关血液学指标分析[J].第三军医大学学报,2010,32(9):975-978.

相似文献/References:

[1]谢燕,喻秀丽,童立纺.硼替佐米对A549细胞增殖及p21、p27表达的影响[J].第三军医大学学报,2012,34(17):1775.
 Xie Yan,Yu Xiuli,Tong Lifang.Anti-proliferation effect of proteasome inhibitor bortezomib in human lung adenocarcinoma A549 cells[J].J Third Mil Med Univ,2012,34(09):1775.
[2]段海玲,熊玮,杨和平,等.误诊为肺癌骨转移的多发性骨髓瘤1例[J].第三军医大学学报,2008,30(10):931.
[3]张超,陈晓红.Syndecan-1在多发性骨髓瘤发病中作用的研究进展[J].第三军医大学学报,2005,27(18):1891.
[4]谢家印,王东,李梦侠,等.APE1/Ref-1 siRNA抑制多发性骨髓瘤骨髓基质细胞IL-6及IL-8分泌的体外研究[J].第三军医大学学报,2009,31(19):1850.
 XIE Jia-yin,WANG Dong,LI Meng-xia,et al.APE1/Ref-1 siRNA inhibits IL-6 and IL-8 secretion by cultured bone marrow stromal cells isolated from multiple myeloma patients[J].J Third Mil Med Univ,2009,31(09):1850.
[5]谢家印,杜佳,李梦侠,等.RNA干扰骨髓基质细胞和/或骨髓瘤细胞APE1表达对共培养骨髓瘤细胞增殖及凋亡的影响[J].第三军医大学学报,2011,33(10):1008.
 Xie Jiayin,Du Jia,Li Mengxia,et al.Effects of RNA interference inhibiting APE1 expression in bone marrow stromal cells and/or U266 cells on proliferation and apoptosis of co-cultured U266[J].J Third Mil Med Univ,2011,33(09):1008.
[6]高力,张曦,高蕾,等.不同来源基质细胞对骨髓瘤KM3细胞增殖和凋亡的影响[J].第三军医大学学报,2009,31(10):879.
 GAO Li,ZHANG Xi,GAO Lei,et al.Effect of stromal cells derived from different origins on proliferation and apoptosis of KM3 cells[J].J Third Mil Med Univ,2009,31(09):879.
[7]樊锐太,胡勇,刘俊启,等.硼替佐米对U87胶质瘤放射增敏及细胞周期分布的影响[J].第三军医大学学报,2012,34(08):758.
 Fan Ruitai,Hu Yong,Liu Junqi,et al.Effect of bortezomib on radiosensitivity of U87 glioma and distribution of cell cycle[J].J Third Mil Med Univ,2012,34(09):758.
[8]李颖,陈建斌,宋君君,等.甲基化修饰致PCDH10基因在多发性骨髓瘤中沉默[J].第三军医大学学报,2012,34(09):817.
 Li Ying,Chen Jianbin,Song Junjun,et al.Methylation induces protocadherin-10 silence in multiple myeloma[J].J Third Mil Med Univ,2012,34(09):817.
[9]侯慧明,张红宾,刘林.IgG型多发性骨髓瘤自体造血干细胞移植后复发合并急性淋巴细胞白血病1例[J].第三军医大学学报,2013,35(13):1361.
[10]张亮,杜佳,周立为,等.依布硒诱导多发性骨髓瘤细胞凋亡及其机制的研究[J].第三军医大学学报,2014,36(02):110.
 Zhang Liang,Du Jia,Zhou Liwei,et al.Ebselen induces apoptosis in human multiple myeloma cell line U226[J].J Third Mil Med Univ,2014,36(09):110.
[11]李佳丽,刘耀,曾东风,等.硼替佐米联合地塞米松和沙利度胺治疗多发性骨髓瘤的临床研究[J].第三军医大学学报,2012,34(24):2515.
 Li Jiali,Liu Yao,Zeng Dongfeng,et al.Bortezomib combined with dexamethasone and thalidomide in treatment of multiple myeloma: report of 58 cases[J].J Third Mil Med Univ,2012,34(09):2515.

更新日期/Last Update: 2010-05-07